Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia

• Main Authors: Hyacinthe Johnson-Ansah (Author), Benjamin Maneglier (Author), Françoise Huguet (Author), Laurence Legros (Author), Martine Escoffre-Barbe (Author), Martine Gardembas (Author), Pascale Cony-Makhoul (Author), Valérie Coiteux (Author), Laurent Sutton (Author), Wajed Abarah (Author), Camille Pouaty (Author), Jean-Michel Pignon (Author), Bachra Choufi (Author), Sorin Visanica (Author), Bénédicte Deau (Author), Laure Morisset (Author), Emilie Cayssials (Author), Mathieu Molimard (Author), Stéphane Bouchet (Author), François-Xavier Mahon (Author), Franck Nicolini (Author), Philippe Aegerter (Author), Jean-Michel Cayuela (Author), Marc Delord (Author), Heriberto Bruzzoni-Giovanelli (Author), Philippe Rousselot (Author)
• Format: Book
• Published: MDPI AG, 2022-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The registered dose for imatinib is 400 mg/d, despite high inter-patient variability in imatinib plasmatic exposure. Therapeutic drug monitoring (TDM) is routinely used to maximize a drug's efficacy or tolerance. We decided to conduct a prospective randomized trial (OPTIM-imatinib trial) to ass...